



PHARMACEUTICAL 2022











PHARMACEUTICAL 2022



Keros Therapeutics Inc. Rank 47 of 466



The relative strengths and weaknesses of Keros Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keros Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 52% points. The greatest weakness of Keros Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 7.9% points.

The company's Economic Capital Ratio, given in the ranking table, is 269%, being 191% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	251,440
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,846
Liabilities, Non-Current	231
Other Assets	2,476
Other Compr. Net Income	0
Other Expenses	2,011
Other Liabilities	0
Other Net Income	-360
Other Revenues	20,100
Property and Equipment	1,335
Research and Development	55,143
Selling, General and Administrative Expense	21,330

Output Variable	Value in 1000 USD
Assets	255,251
Liabilities	12,077
Expenses	78,484
Revenues	20,100
Stockholders Equity	243,174
Net Income	-58,744
Comprehensive Net Income	-58,744
Economic Capital Ratio	269%

